Spero Therapeutics, Inc. (SPRO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1246209,
    "name": "Spero Therapeutics, Inc.",
    "stock_name": "Spero Therapeutics, Inc.",
    "full_name": "Spero Therapeutics, Inc.",
    "name_url": "stocks-analysis/spero-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.28",
    "chg": 0.08,
    "chgp": "3.64%",
    "dir": 1,
    "prev_price": "2.20",
    "mcapval": "112.27",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US84833T1034",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "483.44 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/spero-therapeutics-inc-1246209-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Spero Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-spero-therapeutics-inc-technically-bullish-or-bearish-3547382",
        "imagepath": "",
        "date": "2025-09-20 19:54:05",
        "description": "As of 17 July 2025, the technical trend for Spero Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating a positive trend, while the weekly MACD and Bollinger Bands show a mildly bearish signal. The monthly MACD and Bollinger Bands are mildly bullish, suggesting some strength in the longer term. However, the RSI is bearish on a monthly basis, indicating potential weakness. \n\nIn terms of performance, Spero Therapeutics has outperformed the S&P 500 across multiple periods, with a year-to-date return of 94.17% compared to the S&P's 12.22%, and a one-year return of 49.25% versus 17.14% for the index...."
      },
      {
        "title": "Is Spero Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-spero-therapeutics-inc-overvalued-or-undervalued-3543770",
        "imagepath": "",
        "date": "2025-09-20 18:28:12",
        "description": "As of 27 March 2025, Spero Therapeutics, Inc. has moved from a fair to a risky valuation grade. The company is currently considered overvalued given its high Price to Book Value of 4.13 and negative EV to EBIT and EV to EBITDA ratios of -1.04, indicating significant financial challenges. Additionally, the company's Return on Equity (ROE) is alarmingly low at -203.20%, further underscoring its precarious financial position.\n\nIn comparison to peers, Spero Therapeutics has a worse EV to EBITDA ratio than Shattuck Labs, Inc. at -0.6631 and Enzo Biochem, Inc. at -0.1144, both of which also face risky valuations. Despite the company's strong year-to-date stock return of 94.17% compared to the S&P 500's 12.22%, the long-term outlook remains concerning, particularly with a five-year return of -80.22% against the S&P 500's 96.61%...."
      }
    ],
    "total": 7,
    "sid": "1246209",
    "stock_news_url": "https://www.marketsmojo.com/news/spero-therapeutics-inc-1246209"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Spero Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:54:05

As of 17 July 2025, the technical trend for Spero Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating a positive trend, while the weekly MACD and Bollinger Bands show a mildly bearish signal. The monthly MACD and Bollinger Bands are mildly bullish, suggesting some strength in the longer term. However, the RSI is bearish on a monthly basis, indicating potential weakness. In terms of performance, Spero Therapeutics has outperformed the S&P 500 across multiple periods, with a year-to-date return of 94.17% compared to the S&P's 12.22%, and a one-year return of 49.25% versus 17.14% for the index....

Is Spero Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:28:12

As of 27 March 2025, Spero Therapeutics, Inc. has moved from a fair to a risky valuation grade. The company is currently considered overvalued given its high Price to Book Value of 4.13 and negative EV to EBIT and EV to EBITDA ratios of -1.04, indicating significant financial challenges. Additionally, the company's Return on Equity (ROE) is alarmingly low at -203.20%, further underscoring its precarious financial position. In comparison to peers, Spero Therapeutics has a worse EV to EBITDA ratio than Shattuck Labs, Inc. at -0.6631 and Enzo Biochem, Inc. at -0.1144, both of which also face risky valuations. Despite the company's strong year-to-date stock return of 94.17% compared to the S&P 500's 12.22%, the long-term outlook remains concerning, particularly with a five-year return of -80.22% against the S&P 500's 96.61%....

View All News